ArticlePharmacoEconomics - open2025
A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20% (IgPro20) (Hizentra).
Article in PharmacoEconomics - open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary immune deficiency (PID) comprises over 400 inborn errors of immunity. Immune globulin replacement therapy (IGRT) is the standard of care for many PID subtypes. Intravenous immunoglobulin (IVIG) is the historic standard of care, but subcutaneous immunoglobulin (SCIG) offers several advantages for IGRT. Further, a novel pre-filled syringe (PFS) drug packaging form of SCIG is expected to facilitate more efficient patient infusions.
objectiveThe aim of this study was to quantify the projected budget impact associated with adding the IgPro20 PFS as an SCIG drug packaging option to a health plan formulary for the treatment of PID.
methodsA budget impact model (BIM) was developed across the United States (US) integrated delivery networks (IDNs)' perspective over a 3-year time horizon to quantify the projected budget impact of adding the IgPro20 PFS as an SCIG packaging option for the treatment of PID. Model comparators included six IVIGs and seven SCIGs. A one-way sensitivity analysis was conducted to assess the impact of model parameters on the budget impact. Scenario analyses of alternative market share shifts and pricing were conducted to test the robustness of the model results.
resultsFrom the perspective of an IDN with 25 million members, the average annual expected cost per PID patient was US$73,343 for IgPro20 vials w/pump, US$60,892 for IgPro20 PFS w/pump, US$72,179 for IVIG, and US$96,581 for other SCIGs. Assuming market share uptake of 6.0% in the first year for IgPro20 PFS w/pump, rising to 8.4% by year 3, and offset by corresponding proportionate reductions in shares of the non-PFS SCIG IgPro20 vials w/pump only, the expected incremental budget impact over the 3-year horizon was savings of US$10.5 million.
conclusionThis BIM demonstrates that uptake of subcutaneous IgPro20 PFS is expected to be associated with substantial savings for a US IDN, including drug cost savings if offset by reduced non-PFS SCIG-packaging use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.